Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. More Details
Excellent balance sheet with limited growth.
Share Price & News
How has Xencor's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: XNCR has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: XNCR underperformed the US Biotechs industry which returned 30.7% over the past year.
Return vs Market: XNCR underperformed the US Market which returned 15.6% over the past year.
Price Volatility Vs. Market
How volatile is Xencor's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StHere's Why We're Not Too Worried About Xencor's (NASDAQ:XNCR) Cash Burn Situation
1 month ago | Simply Wall StInvestors Who Bought Xencor (NASDAQ:XNCR) Shares Five Years Ago Are Now Up 91%
2 months ago | Simply Wall StWhat Can We Make Of Xencor's (NASDAQ:XNCR) CEO Compensation?
Is Xencor undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate XNCR's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate XNCR's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: XNCR is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: XNCR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate XNCR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: XNCR is overvalued based on its PB Ratio (3.9x) compared to the US Biotechs industry average (3.3x).
How is Xencor forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XNCR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: XNCR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: XNCR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: XNCR's revenue (39.5% per year) is forecast to grow faster than the US market (10% per year).
High Growth Revenue: XNCR's revenue (39.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if XNCR's Return on Equity is forecast to be high in 3 years time
How has Xencor performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: XNCR is currently unprofitable.
Growing Profit Margin: XNCR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: XNCR is unprofitable, and losses have increased over the past 5 years at a rate of 9.8% per year.
Accelerating Growth: Unable to compare XNCR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XNCR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).
Return on Equity
High ROE: XNCR has a negative Return on Equity (-14.06%), as it is currently unprofitable.
How is Xencor's financial position?
Financial Position Analysis
Short Term Liabilities: XNCR's short term assets ($603.4M) exceed its short term liabilities ($66.4M).
Long Term Liabilities: XNCR's short term assets ($603.4M) exceed its long term liabilities ($7.6M).
Debt to Equity History and Analysis
Debt Level: XNCR is debt free.
Reducing Debt: XNCR has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: XNCR has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if XNCR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Xencor current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate XNCR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate XNCR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if XNCR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if XNCR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of XNCR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bassil Dahiyat (50 yo)
Dr. Bassil I. Dahiyat, Ph.D., Co-founded Xencor, Inc. in August 1997 and has been its President and Chief Executive Officer since February 2005. He serves as Chairman at Xencor Inc. Dr. Dahiyat served as C ...
CEO Compensation Analysis
Compensation vs Market: Bassil's total compensation ($USD3.73M) is about average for companies of similar size in the US market ($USD4.48M).
Compensation vs Earnings: Bassil's compensation has been consistent with company performance over the past year.
|Senior VP & CFO||10yrs||US$1.58m||0.14% |
|Senior VP of Research & Chief Scientific Officer||6.25yrs||US$1.89m||0.15% |
|VP, General Counsel & Corporate Secretary||1.08yrs||US$2.27m||no data|
|Senior VP & Chief Medical Officer||0.83yr||US$2.73m||no data|
|Associate Director and Head of Corporate Communications & Investor Relations||no data||no data||no data|
|Executive Director of Human Resources||0.75yr||no data||no data|
Experienced Management: XNCR's management team is considered experienced (3.7 years average tenure).
|Independent Director||2.83yrs||US$294.30k||0% |
|Member of Scientific Advisory Board||no data||no data||no data|
|Independent Director||5.58yrs||US$333.79k||0% |
|Independent Director||5.25yrs||US$294.63k||0% |
|Independent Director||3.5yrs||US$292.13k||0% |
|Member of Scientific Advisory Board||11.33yrs||no data||no data|
|Independent Director||1.92yrs||US$285.05k||0% |
|Independent Director||6.25yrs||US$297.96k||0% |
|Independent Director||0.83yr||US$306.51k||no data|
Experienced Board: XNCR's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Xencor, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Xencor, Inc.
- Ticker: XNCR
- Exchange: NasdaqGM
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.221b
- Shares outstanding: 57.24m
- Website: https://www.xencor.com
Number of Employees
- Xencor, Inc.
- 111 West Lemon Avenue
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|XNCR||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Dec 2013|
|XE9||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Dec 2013|
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening dise ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/28 00:43|
|End of Day Share Price||2020/10/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.